Pre-made Carotuximab benchmark antibody ( Whole mAb, anti-ENG therapeutic antibody, Anti-END/HHT1/ORW1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-095
Pre-Made Carotuximab biosimilar, Whole mAb, Anti-ENG Antibody: Anti-END/HHT1/ORW1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Carotuximab biosimilar, Whole mAb, Anti-ENG Antibody: Anti-END/HHT1/ORW1 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||National Cancer Institute (USA);Santen Pharmaceutical;TRACON Pharmaceuticals;University of Alabama at Birmingham;University of Minnesota;Roswell Park Cancer Institute|
|Conditions Discontinued||Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Haemangiosarcoma;Choriocarcinoma;Glioblastoma;Liver cancer;Renal cell carcinoma;Soft tissue sarcoma;Breast cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Colorectal cancer;Precursor B-cell lymphoblastic leukaemia-lymphoma;Wet age-related macular degeneration|